Maxcyte (MXCT) Payables (2020 - 2026)

Maxcyte (MXCT) has reported Payables for 7 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables rose 43.31% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 43.31% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 3.17% from the prior year.
• Payables was $1.7 million for Q2 2026 at Maxcyte, up from $1.2 million in the prior quarter.
• Over five years, Payables peaked at $4.4 million in Q1 2022 and troughed at $292000.0 in Q4 2022.
• A 5-year average of $1.7 million and a median of $1.5 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables sank 83.96% in 2022 and surged 317.6% in 2024, its largest moves.
• Over 5 years, Payables stood at $292000.0 in 2022, then surged by 154.45% to $743000.0 in 2023, then surged by 82.77% to $1.4 million in 2024, then gained by 3.17% to $1.4 million in 2025, then climbed by 23.77% to $1.7 million in 2026.
• The last three Payables figures came in at $1.7 million (Q2 2026), $1.2 million (Q1 2026), and $1.4 million (Q4 2025), per Business Quant data.